TCGA-34-5231-01A-21R-1820-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.550
- MYC_TARGETS_V1+0.460
- UNFOLDED_PROTEIN_RESPONSE+0.320
- DNA_REPAIR+0.290
- MITOTIC_SPINDLE+0.240
- INTERFERON_ALPHA_RESPONSE+0.230
- MTORC1_SIGNALING+0.170
- PI3K_AKT_MTOR_SIGNALING+0.170
Top 10 suppressed
- COAGULATION-0.400
- KRAS_SIGNALING_UP-0.400
- TGF_BETA_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.390
- COMPLEMENT-0.370
- HYPOXIA-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.330
- XENOBIOTIC_METABOLISM-0.330
- ESTROGEN_RESPONSE_EARLY-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-63-7023-01A-11R-1949-07 | — | cohortSQ2 | 0.943 |
| 2 | TCGA-38-4630-01A-01R-1206-07 | — | cohortMD1 | 0.916 |
| 3 | TCGA-D8-A1XF-01A-11R-A14D-07 | — | B | 0.892 |
| 4 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.886 |
| 5 | s0095110 | — | — | 0.886 |
| 6 | GSM6454749 | — | F | 0.878 |
| 7 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.873 |
| 8 | TCGA-77-A5GF-01A-21R-A27Q-07 | — | cohortSQ2 | 0.872 |
| 9 | TCGA-NC-A5HG-01A-11R-A26W-07 | — | cohortSQ1 | 0.870 |
| 10 | TCGA-BL-A3JM-01A-12R-A21D-07 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |